These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 407600)

  • 21. Dopaminergic agonists in animal models of parkinsonism.
    Poirier LJ
    Adv Neurol; 1975; 9():327-35. PubMed ID: 807089
    [No Abstract]   [Full Text] [Related]  

  • 22. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.
    Sotnikova TD; Beaulieu JM; Barak LS; Wetsel WC; Caron MG; Gainetdinov RR
    PLoS Biol; 2005 Aug; 3(8):e271. PubMed ID: 16050778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoamine oxidase inhibition by the tremorogenic drug--LON 954.
    Mitra C; Ganguly DK; Guha SR
    J Pharm Pharmacol; 1984 Jun; 36(6):408-10. PubMed ID: 6146677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined low calcium and lack magnesium is a risk factor for motor deficit in mice.
    Taniguchi R; Nakagawasai O; Tan-no K; Yamadera F; Nemoto W; Sato S; Yaoita F; Tadano T
    Biosci Biotechnol Biochem; 2013; 77(2):266-70. PubMed ID: 23391905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment.
    Hausner RS
    J Clin Psychiatry; 1983 Jan; 44(1):13-6. PubMed ID: 6130081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of oxotremorine tremor and hypothermia by injections of drugs into the cerebral ventricles of the mouse.
    Doggett NS; O'Farrell SA
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):149-55. PubMed ID: 1012335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
    Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tremor and dopamine agonists.
    Elble RJ
    Neurology; 2002 Feb; 58(4 Suppl 1):S57-62. PubMed ID: 11909986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals].
    Nomoto M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):113-22. PubMed ID: 8905800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse.
    Kaur S; Starr MS
    Eur J Pharmacol; 1995 Jul; 280(2):159-66. PubMed ID: 7589181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling dyskinesia in animal models of Parkinson disease.
    Morin N; Jourdain VA; Di Paolo T
    Exp Neurol; 2014 Jun; 256():105-16. PubMed ID: 23360802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.
    Jenner P
    Neurology; 2004 Jan; 62(1 Suppl 1):S47-55. PubMed ID: 14718680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    Shiosaki K; Jenner P; Asin KE; Britton DR; Lin CW; Michaelides M; Smith L; Bianchi B; Didomenico S; Hodges L; Hong Y; Mahan L; Mikusa J; Miller T; Nikkel A; Stashko M; Witte D; Williams M
    J Pharmacol Exp Ther; 1996 Jan; 276(1):150-60. PubMed ID: 8558425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacological study of amantadine, a new antiparkinson drug].
    Mori J; Sato Y; Oashi T; Hitomi M
    Nihon Yakurigaku Zasshi; 1974 Jan; 70(1):119-26. PubMed ID: 4858046
    [No Abstract]   [Full Text] [Related]  

  • 36. L-DOPA: chemical modifications and biological evaluation.
    Brossi A; Pool W; Sheppard H; Burns JJ; Kaiser A; Bigler R; Bartholini G; Pletscher A
    Adv Neurol; 1974; 5():291-3. PubMed ID: 4474795
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of elantrine, a new anti-Parkinsonism agent, on drug-induced tremor in mice.
    Ursillo RC; McCulloch JA
    Arch Int Pharmacodyn Ther; 1972 May; 197(1):132-40. PubMed ID: 5031571
    [No Abstract]   [Full Text] [Related]  

  • 38. [Neurochemical aspects of Parkinson tremor].
    Agostini L; Firenze C; Gallai V; Piccinin GL; Piccirilli M; Rossi A
    Clin Ter; 1979 Apr; 89(2):119-25. PubMed ID: 487712
    [No Abstract]   [Full Text] [Related]  

  • 39. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
    Hill MP; Brotchie JM
    Br J Pharmacol; 1999 Dec; 128(7):1577-85. PubMed ID: 10602339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological & biochemical characterization of antiparkinson drugs in reserpinized mice.
    David J; Kaul CL; Grewal RS
    Indian J Exp Biol; 1979 Aug; 17(8):760-4. PubMed ID: 575644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.